Mabylon

About Mabylon

Mabylon AG is a Swiss biotechnology startup focused on leveraging the therapeutic potential of naturally occurring human antibodies. Unlike traditional methods that use humanized animal models or artificial libraries, Mabylon's approach uses antibodies derived directly from humans. This method offers superior therapeutic potential and unique insights into human biology. For example, antibodies from allergic patients can target disease-specific epitopes, which are parts of the allergen that the immune system recognizes. This helps expand our understanding of these epitopes at a molecular level and their role in diseases.

The company primarily operates in the healthcare and biotechnology markets, targeting conditions such as allergies, neurodegenerative diseases, and inflammation. Mabylon's clients include pharmaceutical companies, research institutions, and healthcare providers looking for innovative treatments and deeper biological insights.

Mabylon's business model revolves around research and development (R&D) and partnerships. They conduct extensive R&D to discover and develop new antibody-based therapies. Revenue is generated through licensing agreements, research collaborations, and potentially through the commercialization of their proprietary therapies.

The company's leadership includes notable figures like Adriano Aguzzi, MD, who is a member of the board and a renowned expert in neuropathology. His contributions to the field, such as demonstrating that prions can be halted with therapeutic antibodies, underscore the scientific rigor and innovative potential that Mabylon brings to the table.

In summary, Mabylon AG is at the forefront of biotechnology, using human-derived antibodies to develop groundbreaking treatments for various diseases. Their unique approach not only promises better therapeutic outcomes but also enhances our understanding of human biology.